IUGNF - Imugene (IUGNF) - Three Innovative Platforms That Could Change Cancer Treatment
Three Technology Platforms With Innovative Products Imugene is developing novel immunotherapies that fight cancer by using oncoviruses, gene transfer, and antigen delivery. Its three technology platforms are in development to kill cancer cells directly, replace the use of monoclonal antibodies, or allow the use of CAR-T therapies in sold tumors. Oncolytic Viruses Infect and Kill Cancer Cells. Imugene is developing two products that use modified viruses to target, infect, and kill cancer cells. The infected cells reproduce the virus, infect other cells, and stimulate an immune response. The first product, VAXinia, is in development for several types of metastatic advanced solid tumors. The second product, CHECKVaxx, also stimulates an anti-PD-L1 response for checkpoint inhibition. CHECKVaxx is development for triple negative breast cancer (TNBC).B-Cell Immunotherapies Simulate Antibody Production The B-cell Immunotherapies deliver antigens to the immune system to start production of an endogenous alternative to monoclonal antibodies. These antibodies bind to their targets to block growth pathways and lead to cancer cell death. The lead product, HERVaxx, is several trials for gastric cancer. PD1Vaxx is in development for non-small cell lung cancer (NSCLC).OnCARlytics Could Enable Use Of CAR-T In Solid Tumors The CD19 surface marker it is expressed in blood-cell malignancies and used by CAR-T cells as a targeting mechanism. CF33-CD19 platform delivers a transgene to express the CD19 surface protein in solid tumors, which would enable use of CD19-targeting CAR-T drugs against them.Conclusion. Imugene's technology platforms have products that could compete with or supersede drug categories with several products that generate billions in annual sales. We value the company based on comparable valuations for similar technologies in development, and base our price target on a market valuation of $3.0 billion for a price target of $0.50 per share. Read More >>